labarai
Kula da DNA ƙari mai yawo (ctDNA) daga samfuran jinin marasa lafiya na iya ba da ƙimar ƙima ga ciwon daji mai ci gaba. Jeri da saka idanu akan matakan kewayawar ƙwayar ƙwayar cuta ta DNA ta hanyar ciwon daji Tafiya na jiyya na marasa lafiya na iya taimaka wa likitoci su yanke shawarar tsawon lokaci da ƙarfin zaɓuɓɓukan jiyya.
Menene Rarraba Tumor DNA (ctDNA)?
Ciwon daji DNA (ctDNA) ƙananan guda ne na DNA waɗanda aka zubar daga cikin ciwon daji Kwayoyin cikin jini. Ana samun DNA galibi a cikin tsakiya na sel amma yayin da ƙari ke girma, faɗaɗa kuma ana maye gurbinsu da sabbin ƙwayoyin cuta, ana zubar da DNA daga ƙwayoyin ƙari zuwa yanayin da ke kewaye. Yawan ctDNA na iya bambanta tsakanin masu ciwon daji kuma zai dogara ne akan nau'in ciwon daji, wurinsa da matakin cutar.
Ta yaya kewaya DNA tumor (cTDNA) ke taimakawa?
Bayani game da yawa da jerin ctDNA (Rarraba DNA na tumor) na iya taimakawa tare da gano cutar kansa da hangen nesa, zaɓin zaɓuɓɓukan magani na musamman da kuma ci gaba da sa ido kan cutar don tasirin magani da sake dawowa.
Ta yaya ake yin ctDNA Screening and Assessment?
Ana iya yin gwajin ctDNA daga samfuran jini sabili da haka ana iya yin gwajin DNA na tumor mai yawo sau da yawa yayin cutar mai cutar kansa. Za a iya yin gwajin ctDNA daga jini bisa ga dabaru daban -daban gami da ruwa biopsy da tsarin tsari ko ta hanyar dabarar da ake kira silsilar silsilar polymerase na zamani (ddPCR). Hanyar tsara kwayar halittar cikin ruwa tana ba da cikakken bayani kan takamaiman yanayin maye gurbin kwayoyin halittar cikin kwayoyin halittar cutar kansa da ake gwada su, yakan dauki tsawon lokaci kafin a dawo da sakamakon kuma zai iya zama mafi tsada, saboda haka ba zai yiwu a yi haka ba sau da yawa. Dabarar ddPCR ba ta ba da cikakken bayanin da mutum zai iya samu ta hanyar tsarin ba amma yana da gajeren lokacin juyawa, maras tsada kuma mai yuwuwar sake biya, saboda haka ana iya yin shi akai-akai yayin tafiyar mara lafiya. Hanyar ddPCR na iya ba da bayani game da yawan ctDNA da ke cikin jini amma ba zai iya ba da takamaiman bayanai kan yanayin kwayar cutar ctDNA ba sai dai idan an tsara samfurin.
Abincin da Zai Ci Bayan Bayanan Ciwon Cutar Kansa!
Babu cutar kansa guda biyu iri daya. Wuce ka'idojin abinci mai gina jiki na kowa don kowa kuma yanke hukunci na musamman game da abinci da kari tare da ƙarfin gwiwa.
Nazarin IDEA - ctDNA (kewaya DNA tumor) a cikin Ciwon Kansar
Wani ɗan lokaci na III IDEA-Faransa (Binciken Adjuvant na Duniya na Duniya (IDEA)) na gwaji na marasa lafiya na Stage III, ya kimanta tasirin gajarta (watanni 3) da tsawan (watanni 6) na maganin adana magani na sinadarin oxaliplatin. rayuwa babu cuta. A cikin wannan binciken, masu binciken sun kuma bincika ctDNA na marasa lafiya kafin fara chemotherapy (Andre T. et al, J Jari. Oncol., 2018). Cikakkun bayanai da binciken binciken da nazarin matakan ctDNA tare da rayuwar haƙuri sune kamar haka:
- Adadin marasa lafiya 805 an bincikar da jininsu don ctDNA (yaduwar ƙwayar tumo) kafin fara chemotherapy. Daga cikin waɗannan 696 (86.5%) marasa lafiya sun kasance ctDNA marasa kyau kuma 109 (13.5%) na marasa lafiya sun kasance ctDNA tabbatacce.
- Wadanda ke da ctDNA tabbatacce ciwace-ciwacen an gano suna da ci gaba da ciwan ci gaba tare da rashin bambanci mai kyau.
- Adadin rashin lafiyar cutar na shekaru 2 ga marasa lafiyar ctDNA ya kasance 64% yayin da marasa lafiyar ctDNA ya kasance 82%.
- An lura da yanayin raguwar rayuwa kyauta ga marasa lafiya na ctDNA waɗanda ke cikin babban haɗari ko ƙananan haɗari mataki na III. ciwon daji, kamar yadda bincike mai yawa ya tabbatar.
- Conclusionarshen masu binciken na IDEA game da amfani da sinadarin oxaliplatin a matsayin adjuvant na watanni 3 ko watanni 6 shi ne cewa watanni 6 sun samar da sakamako mafi kyau fiye da maganin wata 3, duka a cikin marasa lafiya da ke da ƙananan samfuran ctDNA ko samfuran ctDNA masu kyau. Koyaya, bambancin rayuwa na shekaru 3 tsakanin watan 6 da 3 na maganin adari na oxaliplatin shine kawai 3.6% tare da watanni 6 cutar rashin lafiyar shekaru 3% da 75.7 wata kasancewa 3%.
Kammalawa daga Nazarin
Bayanan akan nazarin ctDNA daga IDEA binciken colon ciwon daji marasa lafiya, da alaƙa tare da tsira marasa lafiya, an gabatar da su a taron ESMO a watan Satumba, 2019 (Taieb J et al, Abstract LBA30_PR, ESMO Congress, 2019). Wannan bayanan yana nuna cewa kimantawar ctDNA tare da ddPCR na iya zama alamar tsinkaya mai zaman kanta don ci-gaban kansa. Za'a iya haɗa jerin abubuwa da saka idanu na ctDNA (Circular Tumor DNA) a cikin aikin aikin jiyya na mai cutar kansa kuma zai iya taimaka wa likitocin su yanke shawara kan tsawon lokaci da ƙarfin maganin adjuvant wanda mai haƙuri zai buƙaci, dangane da matakan ctDNA kafin fara jiyya.
Abincin da kuke ci kuma wanne kari kuke ɗauka shine yanke shawara. Ya kamata shawararku ta haɗa da la'akari da maye gurbi na ciwon daji, wanda cutar kansa, jiyya da ci gaba da gudana, duk wani rashin lafiyan, bayanin salon rayuwa, nauyi, tsayi da halaye.
Tsarin abinci mai gina jiki don cutar kansa daga addon baya dogara ne akan binciken intanet. Yana sarrafa muku yanke shawara ta atomatik dangane da kimiyyar kwayoyin da masana kimiyya da injiniyoyin software suka aiwatar. Ba tare da la’akari da ko kuna kula da fahimtar hanyoyin hanyoyin kwayoyin halittar biochemical ko a'a - don shirin abinci mai gina jiki don cutar kansa wanda ake buƙatar fahimta.
Fara NOW tare da shirin abinci mai gina jiki ta hanyar amsa tambayoyi kan sunan cutar kansa, maye gurbi, jiyya mai gudana da kari, duk wani rashin lafiyan, halaye, salon rayuwa, ƙungiyar shekaru da jinsi.
Keɓaɓɓen Abinci don Ciwon daji!
Ciwon daji yana canzawa da lokaci. Keɓancewa da canza abincin ku dangane da alamun cutar kansa, jiyya, salon rayuwa, abubuwan da ake so abinci, alerji da sauran dalilai.
Marasa lafiya masu cutar kansa sau da yawa dole su magance daban-daban illar illa na chemotherapy wanda ke shafar rayuwarsu da kuma neman wasu hanyoyin magance cutar kansa madaidaicin abinci mai gina jiki da kari bisa la'akari na kimiyya (guje wa zato da zaɓi bazuwar) shine mafi kyawun maganin ƙasa don cutar kansa da alaƙar magani sakamako masu illa.